Smartwatch Technology's Diagnostic Use in Atrial Fibrillation Detection – A Literature Review

Joshua A. Mikhail, Daniel Tadros, Rafael Shehata
{"title":"Smartwatch Technology's Diagnostic Use in Atrial Fibrillation Detection – A Literature Review","authors":"Joshua A. Mikhail, Daniel Tadros, Rafael Shehata","doi":"10.26685/urncst.475","DOIUrl":null,"url":null,"abstract":"Introduction: An ECG is the gold standard for detecting various cardiology pathologies including AF. Current ambulatory heart rhythm monitoring technology include Holter monitoring and various implantable event monitors, which provide continuous monitoring but are invasive, uncomfortable and may lack in detecting intermittent arrhythmias, due to their periodic exploratory monitoring strategy. Methods: A systematic search was conducted using the following databases: Cochrane Library, Embase, PubMed, and Google Scholar. The search was conducted using the keywords \"atrial fibrillation,\" \"smartwatch,\" \"ECG,\" \"stroke,\" and \"PPG”. Relevant sources between 2018 and 2023 were chosen, and data was analysed to establish clinical utility in early diagnosis of AF. Results: Two studies assessing the diagnostic efficacy of smartwatch technology, two studies investigating the usability of new technology and one study assessing cost-effectiveness were included in our review. The diagnostic efficacy of smartwatches ranges from 93.5-98.25% accurate, 92.45-97.3% sensitive and 88.6-100% specific, with PPV ranging from 91.6-100%, and NPV ranging from 93.85-96.83%. Targeted audiences of AF detection includes a larger proportion of older adults with possible declined technological and/or cognitive function, and may find difficulty using current smartwatch technology. With a simplified user interface, novel software like Pulsewatch promotes user accessibility in smartwatch technology, making AF detection simple to identify, particularly in elderly people. 90 patients used the Pulsewatch system, and more than half reported having a positive experience with the system; only 13% considered it excessively stressful. Discussion: Due to the low 65+ age group representation (6.6%) in studies like Fitbit, Huawei, and Apple heart studies, they overlook potential bias in older adults' adherence to pAF monitoring. Pulsewatch addresses this issue. Smartwatches, being user-friendly and cost-effective, offer real-time, reasonably accurate prospective data for patients. However, further research is required to gauge their clinical utility in early AF detection, diagnostic effectiveness during daily activities, and the heterogeneity of smartwatch devices remains to be fully explored. Conclusion: User-friendly PPG-based smartwatch technology is a medically accurate alternative to standard AF detection techniques that may speed up the diagnosis and treatment of AF, lowering stroke and cardiovascular disease-related morbidity and mortality as well as AF-related healthcare costs.","PeriodicalId":245521,"journal":{"name":"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","volume":"123 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26685/urncst.475","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: An ECG is the gold standard for detecting various cardiology pathologies including AF. Current ambulatory heart rhythm monitoring technology include Holter monitoring and various implantable event monitors, which provide continuous monitoring but are invasive, uncomfortable and may lack in detecting intermittent arrhythmias, due to their periodic exploratory monitoring strategy. Methods: A systematic search was conducted using the following databases: Cochrane Library, Embase, PubMed, and Google Scholar. The search was conducted using the keywords "atrial fibrillation," "smartwatch," "ECG," "stroke," and "PPG”. Relevant sources between 2018 and 2023 were chosen, and data was analysed to establish clinical utility in early diagnosis of AF. Results: Two studies assessing the diagnostic efficacy of smartwatch technology, two studies investigating the usability of new technology and one study assessing cost-effectiveness were included in our review. The diagnostic efficacy of smartwatches ranges from 93.5-98.25% accurate, 92.45-97.3% sensitive and 88.6-100% specific, with PPV ranging from 91.6-100%, and NPV ranging from 93.85-96.83%. Targeted audiences of AF detection includes a larger proportion of older adults with possible declined technological and/or cognitive function, and may find difficulty using current smartwatch technology. With a simplified user interface, novel software like Pulsewatch promotes user accessibility in smartwatch technology, making AF detection simple to identify, particularly in elderly people. 90 patients used the Pulsewatch system, and more than half reported having a positive experience with the system; only 13% considered it excessively stressful. Discussion: Due to the low 65+ age group representation (6.6%) in studies like Fitbit, Huawei, and Apple heart studies, they overlook potential bias in older adults' adherence to pAF monitoring. Pulsewatch addresses this issue. Smartwatches, being user-friendly and cost-effective, offer real-time, reasonably accurate prospective data for patients. However, further research is required to gauge their clinical utility in early AF detection, diagnostic effectiveness during daily activities, and the heterogeneity of smartwatch devices remains to be fully explored. Conclusion: User-friendly PPG-based smartwatch technology is a medically accurate alternative to standard AF detection techniques that may speed up the diagnosis and treatment of AF, lowering stroke and cardiovascular disease-related morbidity and mortality as well as AF-related healthcare costs.
智能手表技术在房颤检测中的诊断应用——文献综述
导语:心电图是检测包括房颤在内的各种心脏病的金标准。目前的动态心律监测技术包括霍尔特监测和各种植入式事件监测仪,这些技术提供连续监测,但由于它们的周期性探索性监测策略,它们具有侵入性,不舒服,并且可能缺乏检测间歇性心律失常的能力。方法:系统检索以下数据库:Cochrane Library、Embase、PubMed和Google Scholar。搜索的关键词是“心房颤动”、“智能手表”、“心电图”、“中风”和“PPG”。选择2018年至2023年的相关来源,并对数据进行分析,以确定AF早期诊断的临床效用。结果:我们的综述纳入了两项评估智能手表技术诊断有效性的研究,两项调查新技术可用性的研究和一项评估成本效益的研究。智能手表的诊断准确率为93.5-98.25%,灵敏度为92.45-97.3%,特异性为88.6-100%,PPV为91.6-100%,NPV为93.85-96.83%。AF检测的目标受众包括较大比例的老年人,他们的技术和/或认知功能可能下降,并且可能难以使用当前的智能手表技术。通过简化的用户界面,像Pulsewatch这样的新颖软件提高了智能手表技术的用户可访问性,使AF检测更容易识别,特别是在老年人中。90名患者使用了Pulsewatch系统,超过一半的患者报告说他们对该系统有积极的体验;只有13%的人认为工作压力过大。讨论:由于在Fitbit、华为和苹果心脏研究等研究中65岁以上年龄组的代表性较低(6.6%),他们忽视了老年人坚持pAF监测的潜在偏见。Pulsewatch解决了这个问题。智能手表具有用户友好性和成本效益,为患者提供实时、合理准确的前瞻性数据。然而,需要进一步的研究来衡量它们在早期房颤检测中的临床应用,日常活动中的诊断有效性,以及智能手表设备的异质性仍有待充分探索。结论:用户友好的基于ppg的智能手表技术是标准房颤检测技术的一种医学上准确的替代技术,可以加快房颤的诊断和治疗,降低卒中和心血管疾病相关的发病率和死亡率,以及房颤相关的医疗成本。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信